{"protocolSection": {"identificationModule": {"nctId": "NCT01842607", "orgStudyIdInfo": {"id": "115661"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects", "officialTitle": "A Multi-centre, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in theMEA115588 or MEA115575 Trials"}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-05-27", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2015-03-13", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-03-13", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-04-25", "studyFirstSubmitQcDate": "2013-04-25", "studyFirstPostDateStruct": {"date": "2013-04-29", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-11-23", "resultsFirstSubmitQcDate": "2016-02-04", "resultsFirstPostDateStruct": {"date": "2016-03-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-08-02", "lastUpdatePostDateStruct": {"date": "2018-08-06", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This is a multi-centre, open-label long-term safety study of 100 milligram (mg) mepolizumab administered subcutaneously (SC) every 4 weeks for 12 months in addition to standard of care in subjects who have severe, refractory asthma and a history of eosinophilic inflammation. Subjects who completed either MEA115588 or MEA115575 will be offered the opportunity to consent for this study."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["eosinophils", "mepolizumab", "SB-240563", "safety", "extension study", "Severe refractory asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 651, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Mepolizumab Arm", "type": "EXPERIMENTAL", "description": "Subjects will receive 100 mg of Mepolizumab (in polypropylene syringe) injected subcutaneously (SC) once every 4 weeks for 12 months", "interventionNames": ["Biological: Mepolizumab"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Mepolizumab", "description": "Mepolizumab (a fully humanised IgG antibody) 100 mg injected SC once every 4 weeks for 12 months. Mepolizumab will be provided as a lyophilised cake in sterile vials", "armGroupLabels": ["Mepolizumab Arm"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Adverse Events (AEs) Including Both Systemic (i.e. Allergic/Immunoglobulin (Ig)E-mediated and Non-allergic) and Local Site Reactions", "description": "AEs were collected from the Baseline visit until the follow-up visit (approx. 12 weeks post-last dose). Participants were monitored to evaluate the AEs of systemic and local site reaction. AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. On treatment AEs were defined as events occurring from the first dose until 28 days after the last dose of mepolizumab.", "timeFrame": "From Baseline visit until the follow-up visit (approximately [approx.] week 60 [12 weeks post-last dose])"}], "secondaryOutcomes": [{"measure": "Number of Participants With Positive Anti-mepolizumab Binding Antibodies and Neutralizing Antibodies (NAb) at the Indicated Time Points", "description": "Blood samples were collected for the determination of anti-mepolizumab antibodies (ADA) just prior to administration of mepolizumab at indicated time points. Samples that tested positive for anti-mepolizumab antibodies were further tested for the presence of NAb. Participants who switched from the 250 mg vial to the 100 mg vial required one immunogenicity sample prior to the first dose from the 100 mg vial and one sample prior to the second dose from the 100 mg vial at the next visit. The highest value post-baseline visit are based on each participant's highest post-baseline titer. NAb assay result was only presented for participants with positive ADA assay. Highest value post-baseline would be positive for a participant who had both negative and positive post-baseline results.", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])"}, {"measure": "Annualized Rate of Exacerbations Per Year", "description": "Exacerbations are defined as the worsening of asthma which requires use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visit. Analysis of the number of exacerbations was performed using a negative binomial model with covariates of region, exacerbations in the year prior to the start of MEA115588 or MEA115575 (as an ordinal variable) and baseline percent (%) predicted forced expiratory volume in 1 second (FEV1), and with logarithm of time on treatment as an offset variable.", "timeFrame": "Baseline up to Exit Visit (approx. 52 weeks) or if Early Withdrawal 4 weeks post last dose"}, {"measure": "Mean Change From Baseline in Asthma Control Questionnaire (ACQ) Score", "description": "The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma control. The five questions enquire about the frequency and/or severity of symptoms (nocturnal awakening on waking in the morning, activity limitation, shortness of breath, wheeze). The response options for all these questions consist of a 0 (no impairment/limitation) to 6 (total impairment/ limitation) scale. The overall ACQ score is calculated as the mean of the 5 questions and therefore ranges between 0 (totally controlled) and 6 (severely uncontrolled). The change from Baseline is defined as the difference between the value of the endpoint at the time point of interest and Baseline value.", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])"}, {"measure": "Mean Change From Baseline in Clinic Pre-bronchodilator FEV1 Over the 52-week Treatment Period", "description": "FEV1 is defined as the volume of air forcefully expelled from the lungs in 1 second. Pre-bronchodilator FEV1 measurements were taken by spirometry at Baseline, Week 16, Week 28 and Week 52. Spirometry was performed within \u00b1 1 hour of the Baseline assessment. The change from Baseline is defined as the difference between the value of the end point at the time point of interest and Baseline value.", "timeFrame": "From Baseline and up to Week 52"}, {"measure": "Number of Participants Withdrawn Due to Lack of Efficacy and Adverse Events From the Study", "description": "AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse.", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])"}, {"measure": "Number of Participants Hospitalized Due to Exacerbations and Adverse Events", "description": "AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Exacerbation is defined as worsening of asthma which requires use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visit.", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])"}, {"measure": "Number of Participants With Systemic (i.e., Allergic/IgE-mediated and Non-allergic) and Local Site Reactions", "description": "Participants were monitored to evaluate the AEs of systemic and local site reaction. AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Hypersensitivity reactions (i.e., allergic or IgE-mediated reactions) were monitored using the diagnostic criteria for anaphylaxis as outlined by the 2006 Joint NIAID/FAAN Second Symposium on Anaphylaxis. Information was also collected to assess localized site reactions as determined by the investigator. On treatment AEs were defined as events occurring from the first dose until 28 days after the last dose of mepolizumab.", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])"}, {"measure": "Number of Participants With Electrocardiogram (ECG) Findings at Any Time Post Baseline", "description": "12-lead ECG measurements were recorded after the participant has rested in the supine position for 5 minutes. The ECG was obtained before lung function testing followed by other study procedures. ECG was performed at Baseline, Week 28, Week 52 and at the end of follow-up period (approx. 12 weeks post-last dose). ECG findings were summarised at any time post Baseline for participants as normal, abnormal-not clinically significant(A-NCS) and abnormal-clinically significant (A-CS).", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])"}, {"measure": "Mean Change From Baseline in QT Interval Corrected by Bazett's Method (QTcB) and QT Interval Corrected by Fridericia's Method (QTcF) Values for ECG Assessed at Baseline, Week 28, Week 52 and at Follow-up Visit (Approx. 12 Weeks Post-last Dose)", "description": "12-lead ECG measurements were recorded after the participant has rested in the supine position for 5 minutes. The ECG was obtained before lung function testing followed by other study procedures. ECG was performed at Baseline, Week 28, Week 52 and at the end of follow-up period (approx. 12 weeks post-last dose). The change from Baseline is defined as the difference between the value of the end point at the time point of interest and Baseline value.", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])"}, {"measure": "Number of Participants With Maximum Change From Baseline in QTcF Interval for ECG Assessed at Any Time Post Baseline", "description": "12-lead ECG measurements were recorded after the participant has rested in the supine position for 5 minutes. ECG was performed at Baseline, Week 28, Week 52 and at the end of follow-up period (approx. 12 weeks post-last dose). Participants with maximum change (MC) from Baseline were summarised at any time post Baseline for the following categories \\<-60, \\>=-60 to \\<-30, \\>=-30 to \\<0, \\>=0 to \\<30, \\>=30 to \\<60 and \\>=60. The change from Baseline is defined as the difference between the value of the end point at the time point of interest and Baseline value. QTc intervals shown at any time post Baseline are the maximum seen in each participant over the course of the trial.", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])"}, {"measure": "Number of Participants With Maximum Change From Baseline in QTcB Interval for ECG Assessed at Any Time Post Baseline", "description": "12-lead ECG measurements were recorded after the participant has rested in the supine position for 5 minutes. ECG was performed at Baseline, Week 28, Week 52 and at the end of follow-up period (approx. 12 weeks post-last dose). Participants with maximum change (MC) from Baseline were summarized at any time post Baseline for the following categories \\<-60, \\>=-60 to \\<-30, \\>=-30 to \\<0, \\>=0 to \\<30, \\>=30 to \\<60 and \\>=60. The change from Baseline is defined as the difference between the value of the end point at the time point of interest and Baseline value. QTc intervals shown at any time post Baseline are the maximum seen in each participant over the course of the trial. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])"}, {"measure": "Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure Assessed at Week 52", "description": "Vital sign measurements including systolic blood pressure (SBP) and diastolic blood pressure (DBP) were performed at Baseline, at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and follow-up visit (approx. 12 weeks post-last dose). Vital measurements were done pre-injection with the participants sitting, having rested in this position for at least 5 minutes before each reading. They were taken before measurement of any clinic lung function tests or ECGs at the specified time point.", "timeFrame": "Baseline and Week 52"}, {"measure": "Change From Baseline in Pulse Rate Assessed at Week 52", "description": "Vital sign measurements including sitting pulse was performed at Baseline, at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and follow-up visit (approx. 12 weeks post-last dose). Vital measurements were done pre-injection with the participants sitting, having rested in this position for at least 5 minutes before each reading. They were taken before measurement of any clinic lung function tests or ECGs at the specified time point.", "timeFrame": "Baseline and Week 52"}, {"measure": "Number of Participants With Clinical Chemistry Parameters Outside the Normal Range at Any Time Post-baseline", "description": "Clinical chemistry laboratory parameters included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bilirubin, calcium, chloride, cholesterol, creatine kinase, creatinine, direct bilirubin, gamma glutamyl transferase, high density lipoprotein (HDL) cholesterol, indirect bilirubin, low density lipoprotein (LDL) cholesterol, lactate dehydrogenase, phosphate, plasma/serum protein, potassium, serum glucose, sodium, triglycerides, urea, and very low density lipoprotein (VLDL) cholesterol assessed at the indicated time points. Laboratory abnormalities outside the normal range (high and low values) at any time post baseline were presented. Any time post Baseline = all visits (including scheduled and unscheduled). If participant had given both high and low value at least once then participant is counted under both high and low category for this visit.", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])"}, {"measure": "Number of Participants With Haematology Laboratory Parameters Outside the Normal Range at Any Time Post-baseline", "description": "Haematology laboratory parameters included basophils, basophils/leukocytes, blood erythrocytes, blood leukocytes, eosinophils, eosinophils/leukocytes, mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), erythrocytes distribution width (EDW), hematocrit, hemoglobin, lymphocytes, lymphocytes/leukocytes, monocytes, monocytes/leukocytes, neutrophils segmented (NS), neutrophils/leukocytes, platelets, reticulocytes assessed at Baseline, Week 4, Week 16, Week 28, Week 52 and follow-up visit (approx. 12 weeks post-last dose). Hematology abnormalities outside the normal range (high and low values) at any time post baseline were presented. Any time post Baseline is equal to all visits (including scheduled and unscheduled) post Baseline were considered for this visit derivation. If participant had given both high and low value at least once then participant is counted under both high and low category for this visit.", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.\n* Informed Consent: Prior to commencing any study related activities, subjects must be able and willing to provide written informed consent.\n* MEA115588 or MEA115575 study completion: Completion of the double-blind investigational product treatment during MEA115588 or MEA115575.\n* Current Anti-Asthma Therapy: Asthma is currently being treated with a controller medication (i.e., inhaled corticosteroids \\[ICS\\] or other asthma controlled medication) and the subject has been on a controller medication for the past 12 weeks. Subjects will be expected to continue controller therapy for the duration of the study.\n* Male or eligible female subjects:\n* To be eligible for entry into the study, females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control for the duration of the trial and for 4 months after the last study drug administration.\n* A serum pregnancy test is required of all females at the initial Baseline Visit (Visit 1). In addition, a urine pregnancy test will be performed for all females prior to enrollment, during each scheduled study visit prior to the injection of investigational product, and during the Follow-up Visit.\n\nExclusion Criteria:\n\n* Hypersensitivity: Hypersensitivity reaction related to study medication during the MEA115588 or MEA115575 that led to patient withdrawal. Subjects who experienced a localized injection site reaction do not need to be excluded.\n* Health Status: Clinically significant change in health status during MEA115588 or MEA115575 which in the opinion of the investigator would make the subject unsuitable for participation in this long-term study.\n* Malignancy: A current malignancy or malignancy that developed during MEA115588 or MEA115575 (subjects that had localized carcinoma of the skin which was resected for cure will not be excluded). \\[Note for South Korea: Korean subjects with a diagnosis of malignancy within 5 years are excluded\\]\n* Prior SAE: A study related SAE in MEA115588 or MEA115575 that was assessed as possibly related to study medication by the investigator.\n* Pregnancy: Subjects who are pregnant or breastfeeding. Subjects should not be enrolled if they plan to become pregnant during the time of study participation.\n* ECG: Baseline ECG which has a clinically significant abnormality or which shows corrected QT interval with Fridericia (QTcF) \\>=450 millisecond (msec) or QTcF \\>=480 msec for subjects with Bundle Branch Block.\n* Smoking status: Current smokers\n* Liver Function: Liver function tests that meet any of the following during one of the last treatment visits in MEA115588 or MEA115575 : alanine transaminase (ALT) \\>=2 x upper limit of normal (ULN); aspartate transaminase (AST) \\>=2 x ULN; alkaline phosphatase \\>=2 x ULN; Bilirubin \\>1.5 x ULN (isolated bilirubin \\>1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is \\<35%\n* Hepatitis Status: Positive Hepatitis B Surface Antigen (HBsAg) screen at Visit 1\n* ECG Over-read: Clinically significant abnormality identified during the central over-read during one of the last treatment visits in MEA115588 or MEA115575", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Long Beach", "state": "California", "zip": "90808", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "GSK Investigational Site", "city": "Newport Beach", "state": "California", "zip": "92663", "country": "United States", "geoPoint": {"lat": 33.61891, "lon": -117.92895}}, {"facility": "GSK Investigational Site", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "GSK Investigational Site", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "GSK Investigational Site", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "GSK Investigational Site", "city": "New Haven", "state": "Connecticut", "zip": "06520", "country": "United States", "geoPoint": {"lat": 41.30815, "lon": -72.92816}}, {"facility": "GSK Investigational Site", "city": "Albany", "state": "Georgia", "zip": "31707", "country": "United States", "geoPoint": {"lat": 31.57851, "lon": -84.15574}}, {"facility": "GSK Investigational Site", "city": "Baltimore", "state": "Maryland", "zip": "21224", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "GSK Investigational Site", "city": "Rochester", "state": "Minnesota", "zip": "55905", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}, {"facility": "GSK Investigational Site", "city": "New York", "state": "New York", "zip": "10029", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "GSK Investigational Site", "city": "Rochester", "state": "New York", "zip": "14642", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "GSK Investigational Site", "city": "Durham", "state": "North Carolina", "zip": "27704", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "GSK Investigational Site", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "GSK Investigational Site", "city": "Cincinnati", "state": "Ohio", "zip": "45229", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "GSK Investigational Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "GSK Investigational Site", "city": "Cleveland", "state": "Ohio", "zip": "44195", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "GSK Investigational Site", "city": "Hershey", "state": "Pennsylvania", "zip": "17033", "country": "United States", "geoPoint": {"lat": 40.28592, "lon": -76.65025}}, {"facility": "GSK Investigational Site", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "PA 15213", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "GSK Investigational Site", "city": "Nashville", "state": "Tennessee", "zip": "37203", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "GSK Investigational Site", "city": "Salt Lake City", "state": "Utah", "zip": "84132", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "GSK Investigational Site", "city": "Mar del Plata", "state": "Buenos Aires", "zip": "7600", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "GSK Investigational Site", "city": "Mar del Plata", "state": "Buenos Aires", "zip": "B7600FZN", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "GSK Investigational Site", "city": "San Rafael", "state": "Mendoza", "zip": "5600", "country": "Argentina", "geoPoint": {"lat": -34.61772, "lon": -68.33007}}, {"facility": "GSK Investigational Site", "city": "Rosario", "state": "Santa Fe", "zip": "S2000DBS", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "GSK Investigational Site", "city": "Buenos Aires", "zip": "C1424BSF", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "GSK Investigational Site", "city": "Ciudad Aut\u00f3noma de Buenos Aires", "zip": "C1426ABP", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "GSK Investigational Site", "city": "Mendoza", "zip": "5500", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "GSK Investigational Site", "city": "New Lambton", "state": "New South Wales", "zip": "2310", "country": "Australia", "geoPoint": {"lat": -32.95, "lon": 151.68333}}, {"facility": "GSK Investigational Site", "city": "Bedford Park", "state": "South Australia", "zip": "5042", "country": "Australia", "geoPoint": {"lat": -35.03333, "lon": 138.56667}}, {"facility": "GSK Investigational Site", "city": "Clayton", "state": "Victoria", "zip": "3168", "country": "Australia", "geoPoint": {"lat": -37.91667, "lon": 145.11667}}, {"facility": "GSK Investigational Site", "city": "Nedlands", "state": "Western Australia", "zip": "6009", "country": "Australia", "geoPoint": {"lat": -31.98184, "lon": 115.8073}}, {"facility": "GSK Investigational Site", "city": "Bruxelles", "zip": "1020", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "GSK Investigational Site", "city": "Gent", "zip": "9000", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "GSK Investigational Site", "city": "Leuven", "zip": "3000", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}, {"facility": "GSK Investigational Site", "city": "Li\u00e8ge", "zip": "4000", "country": "Belgium", "geoPoint": {"lat": 50.63373, "lon": 5.56749}}, {"facility": "GSK Investigational Site", "city": "Calgary", "state": "Alberta", "zip": "T2N 4Z6", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "GSK Investigational Site", "city": "Edmonton", "state": "Alberta", "zip": "T6G 2G3", "country": "Canada", "geoPoint": {"lat": 53.55014, "lon": -113.46871}}, {"facility": "GSK Investigational Site", "city": "Vancouver", "state": "British Columbia", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "GSK Investigational Site", "city": "Winnipeg", "state": "Manitoba", "zip": "R2H 2A6", "country": "Canada", "geoPoint": {"lat": 49.8844, "lon": -97.14704}}, {"facility": "GSK Investigational Site", "city": "Hamilton", "state": "Ontario", "zip": "L8N 4A6", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "GSK Investigational Site", "city": "Montreal", "state": "Quebec", "zip": "H2W 1T8", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "GSK Investigational Site", "city": "Montreal", "state": "Quebec", "zip": "H2X 2P4", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "GSK Investigational Site", "city": "Montreal", "state": "Quebec", "zip": "H4J 1C5", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "GSK Investigational Site", "city": "Quebec City", "state": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "GSK Investigational Site", "city": "St-Charles-Borrom\u00e9e", "state": "Quebec", "zip": "J6E 2B4", "country": "Canada", "geoPoint": {"lat": 46.05007, "lon": -73.46586}}, {"facility": "GSK Investigational Site", "city": "Trois Rivieres", "state": "Quebec", "zip": "G8T 7A1", "country": "Canada", "geoPoint": {"lat": 46.34515, "lon": -72.5477}}, {"facility": "GSK Investigational Site", "city": "Rancagua", "state": "Reg Del Libert Bern Ohiggins", "zip": "2841959", "country": "Chile", "geoPoint": {"lat": -34.17083, "lon": -70.74444}}, {"facility": "GSK Investigational Site", "city": "Santiago", "zip": "8380453", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "GSK Investigational Site", "city": "Talcahuano", "zip": "4270918", "country": "Chile", "geoPoint": {"lat": -36.72494, "lon": -73.11684}}, {"facility": "GSK Investigational Site", "city": "Brno", "zip": "625 00", "country": "Czechia", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"facility": "GSK Investigational Site", "city": "Olomouc", "zip": "775 20", "country": "Czechia", "geoPoint": {"lat": 49.59552, "lon": 17.25175}}, {"facility": "GSK Investigational Site", "city": "Olomouc", "zip": "775 25", "country": "Czechia", "geoPoint": {"lat": 49.59552, "lon": 17.25175}}, {"facility": "GSK Investigational Site", "city": "Praha 4", "zip": "140 00", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "GSK Investigational Site", "city": "Praha 8", "zip": "180 01", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "GSK Investigational Site", "city": "Gi\u00e8res", "zip": "38610", "country": "France", "geoPoint": {"lat": 45.18273, "lon": 5.79179}}, {"facility": "GSK Investigational Site", "city": "Le Kremlin-Bic\u00eatre Cedex", "zip": "94275", "country": "France", "geoPoint": {"lat": 48.81471, "lon": 2.36073}}, {"facility": "GSK Investigational Site", "city": "Lille cedex", "zip": "59037", "country": "France", "geoPoint": {"lat": 50.63297, "lon": 3.05858}}, {"facility": "GSK Investigational Site", "city": "Lyon cedex 04", "zip": "69317", "country": "France", "geoPoint": {"lat": 45.74848, "lon": 4.84669}}, {"facility": "GSK Investigational Site", "city": "Marseille cedex 20", "zip": "13915", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "GSK Investigational Site", "city": "Montpellier cedex 5", "zip": "34295", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "GSK Investigational Site", "city": "Nantes cedex 1", "zip": "44093", "country": "France", "geoPoint": {"lat": 47.21725, "lon": -1.55336}}, {"facility": "GSK Investigational Site", "city": "Paris Cedex 18", "zip": "75877", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "GSK Investigational Site", "city": "Perpignan", "zip": "66000", "country": "France", "geoPoint": {"lat": 42.69764, "lon": 2.89541}}, {"facility": "GSK Investigational Site", "city": "Strasbourg", "zip": "67091", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "GSK Investigational Site", "city": "Aschaffenburg", "state": "Bayern", "zip": "63739", "country": "Germany", "geoPoint": {"lat": 49.97704, "lon": 9.15214}}, {"facility": "GSK Investigational Site", "city": "Ruedersdorf", "state": "Brandenburg", "zip": "15562", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "GSK Investigational Site", "city": "Frankfurt", "state": "Hessen", "zip": "60389", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "GSK Investigational Site", "city": "Frankfurt", "state": "Hessen", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "GSK Investigational Site", "city": "Gelnhausen", "state": "Hessen", "zip": "63571", "country": "Germany", "geoPoint": {"lat": 50.20164, "lon": 9.18742}}, {"facility": "GSK Investigational Site", "city": "Neu-Isenburg", "state": "Hessen", "zip": "63263", "country": "Germany", "geoPoint": {"lat": 50.04832, "lon": 8.69406}}, {"facility": "GSK Investigational Site", "city": "Hannover", "state": "Niedersachsen", "zip": "30173", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "GSK Investigational Site", "city": "Mainz", "state": "Rheinland-Pfalz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "GSK Investigational Site", "city": "Magdeburg", "state": "Sachsen-Anhalt", "zip": "39112", "country": "Germany", "geoPoint": {"lat": 52.12773, "lon": 11.62916}}, {"facility": "GSK Investigational Site", "city": "Luebeck", "state": "Schleswig-Holstein", "zip": "23552", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"facility": "GSK Investigational Site", "city": "Berlin", "zip": "10367", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Hamburg", "zip": "22299", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "GSK Investigational Site", "city": "Napoli", "state": "Campania", "zip": "80131", "country": "Italy", "geoPoint": {"lat": 40.85216, "lon": 14.26811}}, {"facility": "GSK Investigational Site", "city": "Parma", "state": "Emilia-Romagna", "zip": "43100", "country": "Italy", "geoPoint": {"lat": 44.79935, "lon": 10.32618}}, {"facility": "GSK Investigational Site", "city": "Genova", "state": "Liguria", "zip": "16132", "country": "Italy", "geoPoint": {"lat": 44.40478, "lon": 8.94438}}, {"facility": "GSK Investigational Site", "city": "Pietra Ligure (SV)", "state": "Liguria", "zip": "17027", "country": "Italy"}, {"facility": "GSK Investigational Site", "city": "Foggia", "state": "Puglia", "zip": "71100", "country": "Italy", "geoPoint": {"lat": 41.45845, "lon": 15.55188}}, {"facility": "GSK Investigational Site", "city": "Pisa", "state": "Toscana", "zip": "56124", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "GSK Investigational Site", "city": "Perugia", "state": "Umbria", "zip": "06156", "country": "Italy", "geoPoint": {"lat": 43.1122, "lon": 12.38878}}, {"facility": "GSK Investigational Site", "city": "Cittadella (PD)", "state": "Veneto", "zip": "35013", "country": "Italy"}, {"facility": "GSK Investigational Site", "city": "Chiba", "zip": "296-8602", "country": "Japan", "geoPoint": {"lat": 35.6, "lon": 140.11667}}, {"facility": "GSK Investigational Site", "city": "Fukuoka", "zip": "802-0052", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "GSK Investigational Site", "city": "Fukuoka", "zip": "811-1394", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "GSK Investigational Site", "city": "Gunma", "zip": "370-0615", "country": "Japan", "geoPoint": {"lat": 36.52592, "lon": 138.97142}}, {"facility": "GSK Investigational Site", "city": "Hiroshima", "zip": "732-0052", "country": "Japan", "geoPoint": {"lat": 34.4, "lon": 132.45}}, {"facility": "GSK Investigational Site", "city": "Hokkaido", "zip": "070-8644", "country": "Japan", "geoPoint": {"lat": 43.41104, "lon": 142.88878}}, {"facility": "GSK Investigational Site", "city": "Hyogo", "zip": "672-8064", "country": "Japan"}, {"facility": "GSK Investigational Site", "city": "Ibaraki", "zip": "319-1113", "country": "Japan", "geoPoint": {"lat": 34.81641, "lon": 135.56828}}, {"facility": "GSK Investigational Site", "city": "Kanagawa", "zip": "252-0392", "country": "Japan", "geoPoint": {"lat": 37.58333, "lon": 139.91667}}, {"facility": "GSK Investigational Site", "city": "Mie", "zip": "515-8544", "country": "Japan"}, {"facility": "GSK Investigational Site", "city": "Okinawa", "zip": "901-2132", "country": "Japan", "geoPoint": {"lat": 26.33583, "lon": 127.80139}}, {"facility": "GSK Investigational Site", "city": "Okinawa", "zip": "904-2293", "country": "Japan", "geoPoint": {"lat": 26.33583, "lon": 127.80139}}, {"facility": "GSK Investigational Site", "city": "Osaka", "zip": "596-8501", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "102-0083", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "103-0027", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "171-0014", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "187-0024", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Anyang-Si", "zip": "431-070", "country": "Korea, Republic of", "geoPoint": {"lat": 37.3925, "lon": 126.92694}}, {"facility": "GSK Investigational Site", "city": "Bucheon-si,", "zip": "420-767", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "GSK Investigational Site", "city": "Cheongju, Chungcheongbuk-do", "zip": "361-711", "country": "Korea, Republic of"}, {"facility": "GSK Investigational Site", "city": "Daegu", "zip": "705-717", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "GSK Investigational Site", "city": "Donggu Gwangju", "zip": "501757", "country": "Korea, Republic of"}, {"facility": "GSK Investigational Site", "city": "Incheon", "zip": "405-760", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "GSK Investigational Site", "city": "Kangwon-do", "zip": "220-701", "country": "Korea, Republic of"}, {"facility": "GSK Investigational Site", "city": "Seoul", "zip": "120-752", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "GSK Investigational Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "GSK Investigational Site", "city": "Suwon, Kyonggi-do", "zip": "443-721", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "GSK Investigational Site", "city": "Guadalajara", "state": "Jalisco", "zip": "44100", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "GSK Investigational Site", "city": "Monterrey", "state": "Nuevo Le\u00f3n", "zip": "64020", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "GSK Investigational Site", "city": "Amsterdam", "zip": "1105 AZ", "country": "Netherlands", "geoPoint": {"lat": 52.37403, "lon": 4.88969}}, {"facility": "GSK Investigational Site", "city": "Leeuwarden", "zip": "8934 AD", "country": "Netherlands", "geoPoint": {"lat": 53.20139, "lon": 5.80859}}, {"facility": "GSK Investigational Site", "city": "Bialystok", "zip": "15-044", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "GSK Investigational Site", "city": "Krakow", "zip": "31-024", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "GSK Investigational Site", "city": "Chelyabinsk", "zip": "454021", "country": "Russian Federation", "geoPoint": {"lat": 55.15402, "lon": 61.42915}}, {"facility": "GSK Investigational Site", "city": "Moscow", "zip": "123 182", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "GSK Investigational Site", "city": "Saint-Petersburg", "zip": "194354", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "GSK Investigational Site", "city": "St. Petersburg", "zip": "194356", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "GSK Investigational Site", "city": "Alicante", "zip": "03004", "country": "Spain", "geoPoint": {"lat": 38.34517, "lon": -0.48149}}, {"facility": "GSK Investigational Site", "city": "Barcelona", "zip": "08025", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "GSK Investigational Site", "city": "Barcelona", "zip": "08036", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "GSK Investigational Site", "city": "Barcelona", "zip": "08208", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "GSK Investigational Site", "city": "Pozuelo De Alarc\u00f3n/Madrid", "zip": "28223", "country": "Spain"}, {"facility": "GSK Investigational Site", "city": "Kharkiv", "zip": "61124", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Mykolayiv", "zip": "54003", "country": "Ukraine", "geoPoint": {"lat": 46.96591, "lon": 31.9974}}, {"facility": "GSK Investigational Site", "city": "Vinnytsia", "zip": "21018", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "GSK Investigational Site", "city": "Leicester", "state": "Leicestershire", "zip": "LE3 9QP", "country": "United Kingdom", "geoPoint": {"lat": 52.6386, "lon": -1.13169}}, {"facility": "GSK Investigational Site", "city": "Bradford", "zip": "BD9 6RJ", "country": "United Kingdom", "geoPoint": {"lat": 53.79391, "lon": -1.75206}}, {"facility": "GSK Investigational Site", "city": "Liverpool", "zip": "L9 7AL", "country": "United Kingdom", "geoPoint": {"lat": 53.41058, "lon": -2.97794}}, {"facility": "GSK Investigational Site", "city": "London", "zip": "EC1M 6BQ", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "GSK Investigational Site", "city": "Newcastle Upon Tyne", "zip": "NE1 4LP", "country": "United Kingdom", "geoPoint": {"lat": 54.97328, "lon": -1.61396}}, {"facility": "GSK Investigational Site", "city": "Plymouth", "zip": "PL6 8DH", "country": "United Kingdom", "geoPoint": {"lat": 50.37153, "lon": -4.14305}}, {"facility": "GSK Investigational Site", "city": "Southampton", "zip": "SO16 6YD", "country": "United Kingdom", "geoPoint": {"lat": 50.90395, "lon": -1.40428}}]}, "referencesModule": {"references": [{"pmid": "34098955", "type": "DERIVED", "citation": "Gibson PG, Prazma CM, Chupp GL, Bradford ES, Forshag M, Mallett SA, Yancey SW, Smith SG, Bel EH. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions. Respir Res. 2021 Jun 7;22(1):171. doi: 10.1186/s12931-021-01746-4."}, {"pmid": "31507641", "type": "DERIVED", "citation": "Yancey SW, Ortega HG, Keene ON, Bradford ES. Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma. Allergy Asthma Clin Immunol. 2019 Sep 3;15:53. doi: 10.1186/s13223-019-0366-x. eCollection 2019."}, {"pmid": "31447130", "type": "DERIVED", "citation": "Khurana S, Brusselle GG, Bel EH, FitzGerald JM, Masoli M, Korn S, Kato M, Albers FC, Bradford ES, Gilson MJ, Price RG, Humbert M. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. Clin Ther. 2019 Oct;41(10):2041-2056.e5. doi: 10.1016/j.clinthera.2019.07.007. Epub 2019 Aug 22."}, {"pmid": "30954640", "type": "DERIVED", "citation": "Ortega HG, Meyer E, Brusselle G, Asano K, Prazma CM, Albers FC, Mallett SA, Yancey SW, Gleich GJ. Update on immunogenicity in severe asthma: Experience with mepolizumab. J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2469-2475.e1. doi: 10.1016/j.jaip.2019.03.042. Epub 2019 Apr 5. No abstract available."}, {"pmid": "27553751", "type": "DERIVED", "citation": "Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, Yancey SW, Ortega HG. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. Clin Ther. 2016 Sep;38(9):2058-2070.e1. doi: 10.1016/j.clinthera.2016.07.010. Epub 2016 Aug 21."}], "seeAlsoLinks": [{"label": "Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.", "url": "https://www.clinicalstudydatarequest.com"}], "availIpds": [{"id": "115661", "type": "Individual Participant Data Set", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "115661", "type": "Study Protocol", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "115661", "type": "Dataset Specification", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "115661", "type": "Clinical Study Report", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "115661", "type": "Statistical Analysis Plan", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "115661", "type": "Informed Consent Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "115661", "type": "Annotated Case Report Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "651 participants who completed the study MEA115588 or MEA115575 were enrolled in this study. Participants meeting all the inclusion criteria and none of the exclusion criteria received their first mepolizumab dose at Visit 1 and continued to receive mepolizumab subcutaneous (SC) injections approximately every 4 weeks for 12 months.", "recruitmentDetails": "This study was an extension of MEA115588 (NCT01691521) and MEA115575 (NCT01691508). Participants who completed the prior studies were offered to enroll in this study. Assessments that were captured as part of exit visit for MEA115588 and MEA115575 served as Baseline visit for this study.", "groups": [{"id": "FG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "651"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "585"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "66"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "11"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "19"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "8"}]}, {"type": "Protocol defined stopping criteria", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "9"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "14"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "651"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "51.1", "spread": "13.87"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "360"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "291"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "African American/African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}]}]}, {"title": "American Indian or Alaskan Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}]}]}, {"title": "Asian - Central/South Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}]}]}, {"title": "Asian - East Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "44"}]}]}, {"title": "Asian - Japanese Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "45"}]}]}, {"title": "Asian - South East Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}]}]}, {"title": "Native Hawaiian or Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}, {"title": "White - Arabic/North African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}]}]}, {"title": "White - White/Caucasian/European Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "517"}]}]}, {"title": "Mixed Race", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Adverse Events (AEs) Including Both Systemic (i.e. Allergic/Immunoglobulin (Ig)E-mediated and Non-allergic) and Local Site Reactions", "description": "AEs were collected from the Baseline visit until the follow-up visit (approx. 12 weeks post-last dose). Participants were monitored to evaluate the AEs of systemic and local site reaction. AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. On treatment AEs were defined as events occurring from the first dose until 28 days after the last dose of mepolizumab.", "populationDescription": "As Treated (AT) Population: all participants who received at least one dose of open label mepolizumab.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "From Baseline visit until the follow-up visit (approximately [approx.] week 60 [12 weeks post-last dose])", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "651"}]}], "classes": [{"title": "Any AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "558"}]}]}, {"title": "AEs related to study treatment", "categories": [{"measurements": [{"groupId": "OG000", "value": "119"}]}]}, {"title": "Any SAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "94"}]}]}, {"title": "SAEs related to study treatment", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Fatal SAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Positive Anti-mepolizumab Binding Antibodies and Neutralizing Antibodies (NAb) at the Indicated Time Points", "description": "Blood samples were collected for the determination of anti-mepolizumab antibodies (ADA) just prior to administration of mepolizumab at indicated time points. Samples that tested positive for anti-mepolizumab antibodies were further tested for the presence of NAb. Participants who switched from the 250 mg vial to the 100 mg vial required one immunogenicity sample prior to the first dose from the 100 mg vial and one sample prior to the second dose from the 100 mg vial at the next visit. The highest value post-baseline visit are based on each participant's highest post-baseline titer. NAb assay result was only presented for participants with positive ADA assay. Highest value post-baseline would be positive for a participant who had both negative and positive post-baseline results.", "populationDescription": "AT Population. Only those participants available at the indicated timepoints were analyzed (represented by n=X in the category titles).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "651"}]}], "classes": [{"title": "Highest value post-baseline, ADA, positive, n=646", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}]}]}, {"title": "Highest value post-baseline, ADA, negative, n=646", "categories": [{"measurements": [{"groupId": "OG000", "value": "615"}]}]}, {"title": "Highest value post-baseline, NAb, positive, n=31", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Highest value post-baseline, NAb, negative, n=31", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}]}]}]}, {"type": "SECONDARY", "title": "Annualized Rate of Exacerbations Per Year", "description": "Exacerbations are defined as the worsening of asthma which requires use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visit. Analysis of the number of exacerbations was performed using a negative binomial model with covariates of region, exacerbations in the year prior to the start of MEA115588 or MEA115575 (as an ordinal variable) and baseline percent (%) predicted forced expiratory volume in 1 second (FEV1), and with logarithm of time on treatment as an offset variable.", "populationDescription": "AT Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Exacerbations per year", "timeFrame": "Baseline up to Exit Visit (approx. 52 weeks) or if Early Withdrawal 4 weeks post last dose", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "651"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.93", "lowerLimit": "0.83", "upperLimit": "1.04"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Asthma Control Questionnaire (ACQ) Score", "description": "The ACQ-5 is a five-item questionnaire developed as a measure of participants asthma control. The five questions enquire about the frequency and/or severity of symptoms (nocturnal awakening on waking in the morning, activity limitation, shortness of breath, wheeze). The response options for all these questions consist of a 0 (no impairment/limitation) to 6 (total impairment/ limitation) scale. The overall ACQ score is calculated as the mean of the 5 questions and therefore ranges between 0 (totally controlled) and 6 (severely uncontrolled). The change from Baseline is defined as the difference between the value of the endpoint at the time point of interest and Baseline value.", "populationDescription": "AT Population, Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on scale", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "651"}]}], "classes": [{"title": "Week 4, n=603", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.09", "spread": "0.812"}]}]}, {"title": "Week 16, n=592", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.11", "spread": "0.920"}]}]}, {"title": "Week 28, n=577", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.05", "spread": "1.021"}]}]}, {"title": "Week 40, n=564", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.10", "spread": "0.944"}]}]}, {"title": "Week 52, n=556", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.09", "spread": "0.990"}]}]}, {"title": "Follow-up visit, n=338", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.20", "spread": "1.132"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Clinic Pre-bronchodilator FEV1 Over the 52-week Treatment Period", "description": "FEV1 is defined as the volume of air forcefully expelled from the lungs in 1 second. Pre-bronchodilator FEV1 measurements were taken by spirometry at Baseline, Week 16, Week 28 and Week 52. Spirometry was performed within \u00b1 1 hour of the Baseline assessment. The change from Baseline is defined as the difference between the value of the end point at the time point of interest and Baseline value.", "populationDescription": "AT Population, Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Milliliters (mL)", "timeFrame": "From Baseline and up to Week 52", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "651"}]}], "classes": [{"title": "Week 16, n=632", "categories": [{"measurements": [{"groupId": "OG000", "value": "67", "spread": "362.7"}]}]}, {"title": "Week 28, n=615", "categories": [{"measurements": [{"groupId": "OG000", "value": "50", "spread": "409.8"}]}]}, {"title": "Week 52, n=602", "categories": [{"measurements": [{"groupId": "OG000", "value": "29", "spread": "406.2"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Withdrawn Due to Lack of Efficacy and Adverse Events From the Study", "description": "AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse.", "populationDescription": "AT Population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "651"}]}], "classes": [{"title": "Withdrawals due to lack of efficacy", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}]}]}, {"title": "Withdrawals due to adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Hospitalized Due to Exacerbations and Adverse Events", "description": "AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Exacerbation is defined as worsening of asthma which requires use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visit.", "populationDescription": "AT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "651"}]}], "classes": [{"title": "No hospitalisation due to exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "612"}]}]}, {"title": "One time hospitalisation due to exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}]}]}, {"title": "Two times hospitalisation due to exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}]}]}, {"title": "Three times hospitalisation due to exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}]}]}, {"title": "Four times hospitalisation due to exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Five times hospitalisation due to exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Six times hospitalisation due to exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Seven times hospitalisation due to exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Eight times hospitalisation due to exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Nine times hospitalisation due to exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Ten times hospitalisation due to exacerbations", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "No hospitalisation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "560"}]}]}, {"title": "One time hospitalisation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "61"}]}]}, {"title": "Two times hospitalisation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}]}]}, {"title": "Three times hospitalisation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}]}]}, {"title": "Four times hospitalisation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}]}]}, {"title": "Five times hospitalisation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Six times hospitalisation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Seven times hospitalisation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Eight times hospitalisation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Nine times hospitalisation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Ten times hospitalisation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Eleven times hospitalisation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Twelve times hospitalisation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Thirteen times hospitalisation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Fourteen times hospitalisation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Fifteen times hospitalisation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Sixteen times hospitalisation due to AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Systemic (i.e., Allergic/IgE-mediated and Non-allergic) and Local Site Reactions", "description": "Participants were monitored to evaluate the AEs of systemic and local site reaction. AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Hypersensitivity reactions (i.e., allergic or IgE-mediated reactions) were monitored using the diagnostic criteria for anaphylaxis as outlined by the 2006 Joint NIAID/FAAN Second Symposium on Anaphylaxis. Information was also collected to assess localized site reactions as determined by the investigator. On treatment AEs were defined as events occurring from the first dose until 28 days after the last dose of mepolizumab.", "populationDescription": "AT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "651"}]}], "classes": [{"title": "Any systemic infusion/injection site reaction", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}]}]}, {"title": "Injection related reaction", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}]}]}, {"title": "Hypersensitvity", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}]}]}, {"title": "Type IV hypersensitivity reaction", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Any local infusion/injection site reaction", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Electrocardiogram (ECG) Findings at Any Time Post Baseline", "description": "12-lead ECG measurements were recorded after the participant has rested in the supine position for 5 minutes. The ECG was obtained before lung function testing followed by other study procedures. ECG was performed at Baseline, Week 28, Week 52 and at the end of follow-up period (approx. 12 weeks post-last dose). ECG findings were summarised at any time post Baseline for participants as normal, abnormal-not clinically significant(A-NCS) and abnormal-clinically significant (A-CS).", "populationDescription": "AT Population, only participants with ECG results post-baseline were analyzed", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "638"}]}], "classes": [{"title": "Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "262"}]}]}, {"title": "A-NCS", "categories": [{"measurements": [{"groupId": "OG000", "value": "295"}]}]}, {"title": "A-CS", "categories": [{"measurements": [{"groupId": "OG000", "value": "81"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in QT Interval Corrected by Bazett's Method (QTcB) and QT Interval Corrected by Fridericia's Method (QTcF) Values for ECG Assessed at Baseline, Week 28, Week 52 and at Follow-up Visit (Approx. 12 Weeks Post-last Dose)", "description": "12-lead ECG measurements were recorded after the participant has rested in the supine position for 5 minutes. The ECG was obtained before lung function testing followed by other study procedures. ECG was performed at Baseline, Week 28, Week 52 and at the end of follow-up period (approx. 12 weeks post-last dose). The change from Baseline is defined as the difference between the value of the end point at the time point of interest and Baseline value.", "populationDescription": "AT Population, Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Milliseconds (msec)", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "651"}]}], "classes": [{"title": "QTcB, Week 28, n=592", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.5", "spread": "19.10"}]}]}, {"title": "QTcB, Week 52, n=573", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.2", "spread": "18.90"}]}]}, {"title": "QTcB, Follow-up, n=299", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.4", "spread": "19.67"}]}]}, {"title": "QTcF, Week 28, n=592", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.1", "spread": "16.15"}]}]}, {"title": "QTcF, Week 52, n=573", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.5", "spread": "15.68"}]}]}, {"title": "QTcF, Follow-up, n=299", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.5", "spread": "17.01"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Maximum Change From Baseline in QTcF Interval for ECG Assessed at Any Time Post Baseline", "description": "12-lead ECG measurements were recorded after the participant has rested in the supine position for 5 minutes. ECG was performed at Baseline, Week 28, Week 52 and at the end of follow-up period (approx. 12 weeks post-last dose). Participants with maximum change (MC) from Baseline were summarised at any time post Baseline for the following categories \\<-60, \\>=-60 to \\<-30, \\>=-30 to \\<0, \\>=0 to \\<30, \\>=30 to \\<60 and \\>=60. The change from Baseline is defined as the difference between the value of the end point at the time point of interest and Baseline value. QTc intervals shown at any time post Baseline are the maximum seen in each participant over the course of the trial.", "populationDescription": "AT Population, Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "614"}]}], "classes": [{"title": "MC <-60, n=614", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "MC >=-60 to <-30, n=614", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}]}]}, {"title": "MC >=-30 to <0, n=614", "categories": [{"measurements": [{"groupId": "OG000", "value": "252"}]}]}, {"title": "MC >=0 to <30, n=614", "categories": [{"measurements": [{"groupId": "OG000", "value": "328"}]}]}, {"title": "MC >=30 to <60, n=614", "categories": [{"measurements": [{"groupId": "OG000", "value": "20"}]}]}, {"title": "MC >=60, n=614", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Maximum Change From Baseline in QTcB Interval for ECG Assessed at Any Time Post Baseline", "description": "12-lead ECG measurements were recorded after the participant has rested in the supine position for 5 minutes. ECG was performed at Baseline, Week 28, Week 52 and at the end of follow-up period (approx. 12 weeks post-last dose). Participants with maximum change (MC) from Baseline were summarized at any time post Baseline for the following categories \\<-60, \\>=-60 to \\<-30, \\>=-30 to \\<0, \\>=0 to \\<30, \\>=30 to \\<60 and \\>=60. The change from Baseline is defined as the difference between the value of the end point at the time point of interest and Baseline value. QTc intervals shown at any time post Baseline are the maximum seen in each participant over the course of the trial. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).", "populationDescription": "AT Population, Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "614"}]}], "classes": [{"title": "MC <-60, n=614", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "MC >=-60 to <-30, n=614", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}]}]}, {"title": "MC >=-30 to <0, n=614", "categories": [{"measurements": [{"groupId": "OG000", "value": "222"}]}]}, {"title": "MC >=0 to <30, n=614", "categories": [{"measurements": [{"groupId": "OG000", "value": "330"}]}]}, {"title": "MC >=30 to <60, n=614", "categories": [{"measurements": [{"groupId": "OG000", "value": "41"}]}]}, {"title": "MC >=60, n=614", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure Assessed at Week 52", "description": "Vital sign measurements including systolic blood pressure (SBP) and diastolic blood pressure (DBP) were performed at Baseline, at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and follow-up visit (approx. 12 weeks post-last dose). Vital measurements were done pre-injection with the participants sitting, having rested in this position for at least 5 minutes before each reading. They were taken before measurement of any clinic lung function tests or ECGs at the specified time point.", "populationDescription": "AT Population, Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Millimeter of mercury (mmHg)", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "581"}]}], "classes": [{"title": "SBP, Week 52, n=581", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "spread": "12.90"}]}]}, {"title": "DBP, Week 52, n=581", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "9.47"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Pulse Rate Assessed at Week 52", "description": "Vital sign measurements including sitting pulse was performed at Baseline, at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and follow-up visit (approx. 12 weeks post-last dose). Vital measurements were done pre-injection with the participants sitting, having rested in this position for at least 5 minutes before each reading. They were taken before measurement of any clinic lung function tests or ECGs at the specified time point.", "populationDescription": "AT Population, Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Beats per minute (BPM)", "timeFrame": "Baseline and Week 52", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "651"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "spread": "10.52"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Clinical Chemistry Parameters Outside the Normal Range at Any Time Post-baseline", "description": "Clinical chemistry laboratory parameters included alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bilirubin, calcium, chloride, cholesterol, creatine kinase, creatinine, direct bilirubin, gamma glutamyl transferase, high density lipoprotein (HDL) cholesterol, indirect bilirubin, low density lipoprotein (LDL) cholesterol, lactate dehydrogenase, phosphate, plasma/serum protein, potassium, serum glucose, sodium, triglycerides, urea, and very low density lipoprotein (VLDL) cholesterol assessed at the indicated time points. Laboratory abnormalities outside the normal range (high and low values) at any time post baseline were presented. Any time post Baseline = all visits (including scheduled and unscheduled). If participant had given both high and low value at least once then participant is counted under both high and low category for this visit.", "populationDescription": "AT Population, Only those participants available at the specified time points were analyzed ( n=X in the category titles).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "651"}]}], "classes": [{"title": "Alanine aminotransferase, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "70"}]}]}, {"title": "Albumin, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Albumin, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}]}]}, {"title": "Alkaline phosphatase, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "37"}]}]}, {"title": "Aspartate aminotransferase, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "53"}]}]}, {"title": "Bilirubin, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "38"}]}]}, {"title": "Calcium, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}]}]}, {"title": "Calcium, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "49"}]}]}, {"title": "Chloride, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}]}]}, {"title": "Chloride, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "126"}]}]}, {"title": "Cholesterol, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "492"}]}]}, {"title": "Creatine kinase, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "178"}]}]}, {"title": "Creatinine, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "170"}]}]}, {"title": "Creatinine, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "18"}]}]}, {"title": "Direct bilirubin, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}]}]}, {"title": "Gamma glutamyl transferase, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "146"}]}]}, {"title": "HDL cholesterol, Low, n=616", "categories": [{"measurements": [{"groupId": "OG000", "value": "22"}]}]}, {"title": "Indirect bilirubin, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}]}]}, {"title": "LDL cholesterol, High, n=604", "categories": [{"measurements": [{"groupId": "OG000", "value": "207"}]}]}, {"title": "Lactate dehydrogenase, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}]}]}, {"title": "Phosphate, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "149"}]}]}, {"title": "Phosphate, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "84"}]}]}, {"title": "Plasma/serum protein, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}]}]}, {"title": "Potassium, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}]}]}, {"title": "Potassium, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "22"}]}]}, {"title": "Serum glucose, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "62"}]}]}, {"title": "Serum glucose, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "239"}]}]}, {"title": "Sodium, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}]}]}, {"title": "Sodium, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}]}]}, {"title": "Triglycerides, High, n=617", "categories": [{"measurements": [{"groupId": "OG000", "value": "102"}]}]}, {"title": "Urea, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}]}]}, {"title": "Urea, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "53"}]}]}, {"title": "VLDL cholesterol, Low, n=605", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}]}]}, {"title": "VLDL cholesterol, High, n=605", "categories": [{"measurements": [{"groupId": "OG000", "value": "99"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Haematology Laboratory Parameters Outside the Normal Range at Any Time Post-baseline", "description": "Haematology laboratory parameters included basophils, basophils/leukocytes, blood erythrocytes, blood leukocytes, eosinophils, eosinophils/leukocytes, mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), erythrocytes distribution width (EDW), hematocrit, hemoglobin, lymphocytes, lymphocytes/leukocytes, monocytes, monocytes/leukocytes, neutrophils segmented (NS), neutrophils/leukocytes, platelets, reticulocytes assessed at Baseline, Week 4, Week 16, Week 28, Week 52 and follow-up visit (approx. 12 weeks post-last dose). Hematology abnormalities outside the normal range (high and low values) at any time post baseline were presented. Any time post Baseline is equal to all visits (including scheduled and unscheduled) post Baseline were considered for this visit derivation. If participant had given both high and low value at least once then participant is counted under both high and low category for this visit.", "populationDescription": "AT Population, Only those participants available at the specified time points were analyzed ( n=X in the category titles).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "From Baseline visit until the follow-up visit (approx. week 60 [12 weeks post-last dose])", "groups": [{"id": "OG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "651"}]}], "classes": [{"title": "Basophils, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Basophils/Leukocytes, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Blood Erythrocytes, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "52"}]}]}, {"title": "Blood Erythrocytes, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}]}]}, {"title": "Blood Leukocytes, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}]}]}, {"title": "Blood Leukocytes, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "146"}]}]}, {"title": "Eosinophils, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "429"}]}]}, {"title": "Eosinophils, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "51"}]}]}, {"title": "Eosinophils/Leukocytes, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "60"}]}]}, {"title": "MCHC, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "276"}]}]}, {"title": "MCH, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "58"}]}]}, {"title": "MCH, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}]}]}, {"title": "MCV, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "32"}]}]}, {"title": "MCV, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "32"}]}]}, {"title": "EDW, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "322"}]}]}, {"title": "Hematocrit, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "57"}]}]}, {"title": "Hematocrit, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "94"}]}]}, {"title": "Hemoglobin, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "116"}]}]}, {"title": "Hemoglobin, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}]}]}, {"title": "Lymphocytes, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "48"}]}]}, {"title": "Lymphocytes, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}]}]}, {"title": "Lymphocytes/Leukocytes, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "168"}]}]}, {"title": "Lymphocytes/Leukocytes, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "68"}]}]}, {"title": "Monocytes, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "156"}]}]}, {"title": "Monocytes, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}]}]}, {"title": "Monocytes/Leukocytes, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}]}]}, {"title": "NS, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}]}]}, {"title": "NS, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "151"}]}]}, {"title": "Neutrophils/Leukocytes, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "39"}]}]}, {"title": "Neutrophils/Leukocytes, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "226"}]}]}, {"title": "Platelets, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}]}]}, {"title": "Platelets, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "58"}]}]}, {"title": "Reticulocytes, Low, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "77"}]}]}, {"title": "Reticulocytes, High, n=649", "categories": [{"measurements": [{"groupId": "OG000", "value": "294"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "Adverse events (AEs) and Serious adverse events (SAEs) were collected from the first dose of study treatment until 28 days after the last dose of mepolizumab up to 52 weeks.", "description": "Serious adverse events (SAEs) and Non-serious AEs were collected in members of As-Treated (AT) Population, comprised of all participants who received at least one dose of open label mepolizumab medication.", "eventGroups": [{"id": "EG000", "title": "Mepolizumab 100 mg SC", "description": "Participants received mepolizumab 100 milligrams (mg) administered via subcutaneous (SC) injection into the upper arm or thigh approximately every 4 weeks for 12 months. Participants remained on standard of care asthma therapy which could be adjusted during the study at the discretion of the physician.", "seriousNumAffected": 94, "seriousNumAtRisk": 651, "otherNumAffected": 461, "otherNumAtRisk": 651}], "seriousEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 38, "numAtRisk": 651}]}, {"term": "Atelectasis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Respiratory distress", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Sleep apnoea syndrome", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 651}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 651}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 651}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 651}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 651}]}, {"term": "Aspergillus infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Chronic sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Enteritis infectious", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "H1N1 influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Labyrinthitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Pharyngeal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Pyelonephritis acute", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Staphylococcal bacteraemia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Wound infection staphylococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Dyskinesia oesophageal", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Haemorrhoids", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Ileus paralytic", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Lower gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Acetabulum fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Brain contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Fibula fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Radius fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Skull fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Spinal compression fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Thermal burn", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Tibia fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 651}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Cardio-respiratory arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Hypertensive heart disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Mitral valve incompetence", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Spondylolisthesis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Vertebral foraminal stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Benign salivary gland neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Bladder cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Endometrial cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Gastric cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Cerebral haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Restless legs syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "VIIth nerve paralysis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Gallbladder disorder", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Jaundice cholestatic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Anaphylactic shock", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Type IV hypersensitivity reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Panic attack", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Nephrocalcinosis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Urinary tract pain", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Retinal detachment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Ejection fraction decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Ovarian cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 651}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 196, "numAtRisk": 651}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 99, "numAtRisk": 651}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 78, "numAtRisk": 651}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 66, "numAtRisk": 651}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 28, "numAtRisk": 651}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 651}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 651}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 21, "numAtRisk": 651}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 46, "numAtRisk": 651}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 44, "numAtRisk": 651}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 21, "numAtRisk": 651}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 21, "numAtRisk": 651}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 61, "numAtRisk": 651}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 34, "numAtRisk": 651}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 651}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 87, "numAtRisk": 651}]}, {"term": "Injection site reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 29, "numAtRisk": 651}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 24, "numAtRisk": 651}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 27, "numAtRisk": 651}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 21, "numAtRisk": 651}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Czech Republic"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M4225", "name": "Antibodies", "relevance": "LOW"}, {"id": "M10122", "name": "Immunoglobulin G", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}